Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.

Abstract: The invention relates to vector constructs for an HIV-specific gene therapy. The expression of transgenes is coupled with an infection of the cell with HIV while the transcription of the transgene is controlled by a transcription control region derived from HIV. In addition, the transgene is improved with regard to RNA stability and expression efficiency by modifying the nucleotide sequence.

Abstract: The present invention relates to reporter systems for RNA export, methods for searching for molecules which influence RNA export, and a method, based on these methods, for detecting a viral infection.

Abstract: The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.

Abstract: An integrated programmable device has a plurality of signal inputs (P1, P2, P3) connected to respective ones of a plurality of switching elements (S1, S2, S3). Each switching element (S1, S2, S3) has an associated enable line (E1, E2, E3). A control circuit (15) activates one or more selected signal inputs (P1-P3) in accordance with a channel select signal (16) via these enable lines (E1, E2, E3). Feedback lines (F1, F2, F3) are connected to corresponding enable lines (E1, E2, E3) to a channel feedback indicative of which signal inputs (P1, P2, P3) is enabled. This allows determination whether the enabled signal inputs (P1, P2, P3) correspond to the channel select signal (16) and initiates an exception handling in case of a mismatch. The comparison can be performed by a compare logic circuit (40) or the channel feedback can be stored in a memory (30) accessible by a software program (60), which performs the comparison.

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: A release device for actuating a clamping device for tools has at least one release element and a drive drivingly connected to the at least one release element for moving the at least one release element from a rest position into a release position in which a draw bar of the clamping device is moved against a clamping force into a disengaged position. The drive is an electric motor. The axis of the electric motor can be aligned with the axis of the release device but an angled arrangement of the electric motor and of the release device relative to one another is also possible.

Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.

Abstract: An integrated programmable device has a plurality of signal inputs (P1, P2, P3) connected to respective ones of a plurality of switching elements (S1, S2, S3). Each switching element (S1, S2, S3) has an associated enable line (E1, E2, E3). A control circuit (15) activates one or more selected signal inputs (P1-P3) in accordance with a channel select signal (16) via these enable lines (E1, E2, E3). Feedback lines (F1, F2, F3) are connected to corresponding enable lines (E1, E2, E3) to a channel feedback indicative of which signal inputs (P1, P2, P3) is enabled. This allows determination whether the enabled signal inputs (P1, P2, P3) correspond to the channel select signal (16) and initiates an exception handling in case of a mismatch. The comparison can be performed by a compare logic circuit (40) or the channel feedback can be stored in a memory (30) accessible by a software program (60), which performs the comparison.

Abstract: The present invention relates to animal viruses such as animal herpesviruses as a vector for diagnostic, therapeutic and prophylactic delivery of foreign genes and nucleic acids to animals, human or primary cells derived thereof, respectively. By using said viruses, the prevention and treatment of infectious, autoimmune and tumor diseases as well as allergies and genetic disorders can be treated. The present invention relates further to procedures to efficiently transduce primary human cells with recombinant animal viruses in vitro and in vivo. The invention further relates to a kit useful (i) for diagnosis and monitoring of innate and adoptive immune responses as well as (ii) for gene therapy and (iii) immunization purposes.

Abstract: A shank-end tool is described that is simple and economical to manufacture, with permanently attached wing-like inserts for the milling-type machining of chipless materials that remains functional with unavoidable frictional wear and with increasing erosion. The shank-end tool is characterized by a shank (1) rotatable around its longitudinal axis (2) that can be connected detachably to a drive device and is provided at its free end section (6) with at least one groove-shaped recess (7) extending in the axial direction and one flat cutter blade (8), which is provided with a non-cutting blade edge (12) on its leading face viewed in the direction of advance (9). The shank-end tool is used for the manufacture of molds, especially heat-resistant casting molds for the production of metal castings.

Abstract: In a method for adjusting at least one pressing element of a molding machine for machining workpieces of wood or plastic material relative to a workpiece, transported through the machine and to be machined by the machine, the pressing element is adjusted outside of the molding machine in an adjusting device with the aid of a template of the workpiece and the adjusted pressing element is then inserted into the molding machine.

Abstract: A release device for actuating a clamping device for tools has at least one release element and a drive drivingly connected to the at least one release element for moving the at least one release element from a rest position into a release position in which a draw bar of the clamping device is moved against a clamping force into a disengaged position. The drive is an electric motor. The axis of the electric motor can be aligned with the axis of the release device but an angled arrangement of the electric motor and of the release device relative to one another is also possible.

Abstract: The present invention relates to the use a Phyllanthus extract or a fraction thereof or a gallotannin or a combination of gallotannins for the preparation of a pharmaceutical composition for the prevention or treatment of retrovirus related diseases associated with a nucleosidic inhibitor-resistant retrovirus and/or a non-nucleosidic inhibitor-resistant retrovirus. Preferably, the retrovirus is a human immunodeficiency virus (HIV). In accordance with the present invention, it is further preferred that said gallotannin or combination of gallotannins is or comprises corilagin and/or geraniin and another ellagitannin. Further preferred is that said Phyllanthus is Phyllanthus amarus.

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.